Europe is facing a growing threat from Candidozyma auris, a hospital-spreading fungus resistant to many treatments. The European Centre for Disease Prevention and Control (ECDC) recently released a report confirming a sharp rise in cases and warning that transmission has become endemic in several countries. We asked Biosergen CEO Tine Olesen what this means for the company’s ongoing development of antifungal candidate BSG005.

Read the full interview at biostock.se:

ECDC raises alarm about C. auris – Biosergen wants to contribute to the solution

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!  

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Läs mer på BioStock

Ämnen i artikeln

Biosergen

Senast

0,46

1 dag %

−4,18%

1 dag

1 mån

1 år

Marknadsöversikt

OMX Stockholm 30

1 DAG %

−0,41%

Senast

2 733,11

1 mån
Loading market data...
Börsveckans arkiv
Börsveckan omslag

Läs alla nummer av Börsveckan här.